Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274

Cytokinetics (Nasdaq:CYTK) announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274) in healthy adult subjects.

As quoted in the press release:

“The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “Our scientists pioneered this emerging area of muscle pharmacology and have now advanced a next-generation drug candidate that was optimized for pharmacokinetic properties and therapeutic index. This first trial will elaborate on CK-274 and its potential to be best-in-class and we look forward to reporting data in 2019.”

The primary objective of this Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose trial is to assess the safety and tolerability of single and multiple oral doses of CK-274. The study design includes eight single ascending dose cohorts and three multiple ascending dose cohorts, with eight healthy subjects per cohort. Additional objectives include describing the pharmacokinetics (PK) of CK-274 and its pharmacodynamic effects (PD) as measured by echocardiography, as well as characterizing the relationship between the two with regards to cardiac function. Additional information can be found on www.clinicaltrials.gov.

Click here to read the full press release.